These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24347427)

  • 1. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
    Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
    Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic characterization of adrenocortical carcinoma.
    Assié G; Letouzé E; Fassnacht M; Jouinot A; Luscap W; Barreau O; Omeiri H; Rodriguez S; Perlemoine K; René-Corail F; Elarouci N; Sbiera S; Kroiss M; Allolio B; Waldmann J; Quinkler M; Mannelli M; Mantero F; Papathomas T; De Krijger R; Tabarin A; Kerlan V; Baudin E; Tissier F; Dousset B; Groussin L; Amar L; Clauser E; Bertagna X; Ragazzon B; Beuschlein F; Libé R; de Reyniès A; Bertherat J
    Nat Genet; 2014 Jun; 46(6):607-12. PubMed ID: 24747642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of adrenocortical cancer.
    Bertherat J; Bertagna X
    Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):261-71. PubMed ID: 19500768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
    Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
    Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
    Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
    Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
    Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetics of adrenocortical tumors.
    Espiard S; Bertherat J
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):311-34. PubMed ID: 26038203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of TP53 alterations in adrenocortical carcinomas.
    Waldmann J; Patsalis N; Fendrich V; Langer P; Saeger W; Chaloupka B; Ramaswamy A; Fassnacht M; Bartsch DK; Slater EP
    Langenbecks Arch Surg; 2012 Feb; 397(2):209-16. PubMed ID: 22203015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers and the pathogenesis of adrenocortical cancer.
    Soon PS; McDonald KL; Robinson BG; Sidhu SB
    Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.
    De Martino MC; Al Ghuzlan A; Aubert S; Assié G; Scoazec JY; Leboulleux S; Do Cao C; Libè R; Nozières C; Lombès M; Pattou F; Borson-Chazot F; Hescot S; Mazoyer C; Young J; Borget I; Colao A; Pivonello R; Soria JC; Bertherat J; Schlumberger M; Lacroix L; Baudin E
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4080-8. PubMed ID: 23979958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of adrenocortical carcinomas.
    Soon PS; Sidhu SB
    Minerva Endocrinol; 2009 Jun; 34(2):137-47. PubMed ID: 19471238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Next Generation Sequencing molecular profiling and its clinical application in adrenocortical cancer.
    Cioppi F; Cantini G; Ercolino T; Chetta M; Zanatta L; Nesi G; Mannelli M; Maggi M; Canu L; Luconi M
    Eur J Endocrinol; 2024 Jul; 191(1):17-30. PubMed ID: 38917236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
    Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
    J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.